secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021275
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track
--------------------------------------------------------------------------------

- Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.
- R&D expenses $12.0M (up from $5.6M); G&A expenses $4.1M (up from $2.1M).
- Cash, cash equivalents and investments totaled $88.5M at March 31, 2023.
- Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease.
- Expects to complete Phase 2 enrollment mid-2023; top-line data ~9 months after enrollment completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/0000950170-23-021275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017023021275/antx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer